SCHEMBL3589190

SCHEMBL3589190

N#CCC(=O)c1ccc(F)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
KCNQ3 O43525 1/20 0.40
KCNQ2 O43526 1/20 0.40
KCNE1 P15382 1/20 0.40
KCNQ1 P51787 1/20 0.40
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
S1PR3 Q99500 2/20 0.40
S1PR2 O95136 1/20 0.40
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40
KCNH2 Q12809 1/20 0.40
TSHR P16473 1/20 0.40
PIK3CA P42336 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31410597 0.87 KCNQ3 (0.42) KCNQ3KCNQ2KCNE1KCNQ1CES2
SCHEMBL133027 0.84 TSHR (0.52) TSHR
SCHEMBL11345564 0.84 CES2 (0.59) MAOAMAOBKCNQ3KCNQ2CES2
SCHEMBL29484265 0.84 CES2 (0.59) MAOAMAOBKCNQ3KCNQ2CES2
SCHEMBL30712974 0.84 TSHR (0.52) TSHR
SCHEMBL12694460 0.81 HSP90AA1 (0.49) KCNH2TSHRSMN1; SMN2
SCHEMBL26690772 0.81 P4HB (0.47) CES2CES1
SCHEMBL7144096 0.79 GSK3B (0.59) MAOAMAOBKCNQ3KCNQ2KCNE1
SCHEMBL27503767 0.79 KCNQ3 (0.44) MAOAMAOBKCNQ3KCNQ2KCNE1
SCHEMBL138022 0.78 GSK3B (0.57) CES2CES1KCNH2TSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100063065-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I INPHARMATICA LIMITED (GB) 2010-03-11 US disclosed
EP-1937663-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I Inpharmatica Limited (GB) 2008-07-02 EP disclosed
WO-2007036730-A9 THIOPHENE DERIVATIVES AS PPAR AGONISTS I INPHARMATICA LTD (GB) 2008-06-19 WO disclosed
WO-2007036730-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I INPHARMATICA LIMITED (GB) 2007-04-05 WO disclosed
US-20060046999-A1 Monocyclic aroylpyridinones as antiinflammatory agents BAYER HEALTHCARE AG (DE) 2006-03-02 US disclosed
EP-1487794-A1 MONOCYCLIC AROYLPYRIDINONES AS ANTIINFLAMMATORY AGENTS Bayer Aktiengesellschaft (DE) 2004-12-22 EP disclosed
WO-2003076405-A1 MONOCYCLIC AROYLPYRIDINONES AS ANTIINFLAMMATORY AGENTS BAYER HEALTHCARE AG (DE) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046999-A1 Monocyclic aroylpyridinones as antiinflammatory agents PTGIS, PTGES, PTGES2 MAOA 543/4885MAOB 682/4885KCNQ3 3436/4885
US-20100063065-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I PPARG, PPARD, PPARA MAOA 4440/4885MAOB 3961/4885KCNQ3 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.